FOLH1 and prostate cancer: The combination of PSMA PET/CT and MRI seems to be superior to MRI alone in the diagnostic performance for detecting clinical significant prostate cancer (csPC), thus potentially allowing a better selection and even a reduction in the number of prostate biopsies.